A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia

Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost...

Full description

Saved in:

Bibliographic Details
Published in:	PloS one Vol. 17; no. 4; p. e0266824
Main Authors:	Chughtai, Bilal, Rojanasarot, Sirikan, Neeser, Kurt, Gultyaev, Dmitry, Fu, Shuai, Bhattacharyya, Samir K., El-Arabi, Ahmad M., Cutone, Ben J., McVary, Kevin T.
Format:	Journal Article
Language:	English
Published:	United States Public Library of Science 15.04.2022 Public Library of Science (PLoS)
Subjects:	Aged Analysis Biology and Life Sciences Clinical trials Cost analysis Cost-Benefit Analysis Costs Economic aspects Genital diseases Government programs Health aspects Health care policy Health services Humans Hyperplasia Hypertrophy Intubation Literature reviews Male Markov chains Medical fees Medicare Medicine and Health Sciences Meta-analysis Middle Aged Patients Physical Sciences Prostate Prostatic Hyperplasia - complications Quality of Life Social Sciences Transurethral Resection of Prostate - adverse effects Treatment Outcome United States Urinary tract Urogenital system Vaporization Water vapor United States New York United States > US Germany
ISSN:	1932-6203, 1932-6203
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm 3 . A random-effects network meta‐analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments.
AbstractList	Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta‐analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments. Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume [less than or equal to]80 cm.sup.3 . A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments. Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments.Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments. Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm 3 . A random-effects network meta‐analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments.
Audience	Academic
Author	Cutone, Ben J. McVary, Kevin T. Bhattacharyya, Samir K. Rojanasarot, Sirikan Neeser, Kurt El-Arabi, Ahmad M. Fu, Shuai Gultyaev, Dmitry Chughtai, Bilal
AuthorAffiliation	4 Center for Male Health, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, United States of America 2 Boston Scientific, Marlborough, MA, United States of America 1 Department of Urology, Weill Cornell Medicine, New York, New York, United States of America 3 Certara Evidence & Access, Lörrach, BW, Germany University Medical Center Utrecht, NETHERLANDS
AuthorAffiliation_xml	– name: 4 Center for Male Health, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, United States of America – name: University Medical Center Utrecht, NETHERLANDS – name: 1 Department of Urology, Weill Cornell Medicine, New York, New York, United States of America – name: 2 Boston Scientific, Marlborough, MA, United States of America – name: 3 Certara Evidence & Access, Lörrach, BW, Germany
Author_xml	– sequence: 1 givenname: Bilal surname: Chughtai fullname: Chughtai, Bilal – sequence: 2 givenname: Sirikan orcidid: 0000-0003-2102-7520 surname: Rojanasarot fullname: Rojanasarot, Sirikan – sequence: 3 givenname: Kurt surname: Neeser fullname: Neeser, Kurt – sequence: 4 givenname: Dmitry surname: Gultyaev fullname: Gultyaev, Dmitry – sequence: 5 givenname: Shuai surname: Fu fullname: Fu, Shuai – sequence: 6 givenname: Samir K. surname: Bhattacharyya fullname: Bhattacharyya, Samir K. – sequence: 7 givenname: Ahmad M. surname: El-Arabi fullname: El-Arabi, Ahmad M. – sequence: 8 givenname: Ben J. surname: Cutone fullname: Cutone, Ben J. – sequence: 9 givenname: Kevin T. surname: McVary fullname: McVary, Kevin T.
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35427376$$D View this record in MEDLINE/PubMed
BookMark	eNqNk9lq3DAUhk1JaZb2DUprKJQWMlMttmT3ohBCl0Ag0O1WyPLRjFKN5Ehy6LxFH7maJSETQim-sDn6_l86x78Oiz3nHRTFc4ymmHL87tKPwUk7HXJ5ighjDakeFQe4pWTCCKJ7d773i8MYLxGqacPYk2Kf1hXhlLOD4s9JqfxiCDAHF801lDJ7LqOJpdelssYZJe1xeTVKa9JyVbRGw3HG-iyMaQJag0pZ6SBm0ZiyHazVv2BZpgAyLcCl0g_JeBdL7UPZgTMzVw4hG8hkVDlfDhAGK6ORT4vHWtoIz7bvo-LHp4_fT79Mzi8-n52enE8UQ7yatC3hGusaQ9dDi6VUXac40ayVfV8R1dWs7epKVpojqFjNEMG6lxVmTaVrqehR8XLjO1gfxXaYURBWI9pyXNeZONsQvZeXYghmIcNSeGnEuuDDTMiQT29BIEk5aZHitOIVlrzVTaNY30HfkI61Ont92O42dgvoVZ5IkHbHdHfFmbmY-WvRIkwoq7LBm61B8FcjxCQWJiqwVjrw4_rcuTXGKM_oq3vow91tqZnMDRinfd5XrUzFCc9JaRAhNFPTB6j89LAwKidPm1zfEbzdEWQmwe80k2OM4uzb1_9nL37usq_vsHOQNs2jt-M6VLvgi7uTvh3xTeQzUG0AleMXA-hbBCOxulk34xKrmyW2NyvL3t-TKbMKr1_9L2P_Lf4L_fAsCA
CitedBy_id	crossref_primary_10_1016_j_urology_2025_07_016 crossref_primary_10_1080_19325037_2025_2552667 crossref_primary_10_1148_radiol_230555 crossref_primary_10_1089_end_2023_0766 crossref_primary_10_1016_j_urology_2022_09_026 crossref_primary_10_1038_s41391_025_00986_5 crossref_primary_10_1016_j_ultsonch_2025_107223 crossref_primary_10_1016_j_urology_2023_06_005 crossref_primary_10_3389_fruro_2023_1100386 crossref_primary_10_1159_000547152 crossref_primary_10_1016_j_fjurol_2025_102872 crossref_primary_10_7759_cureus_61295 crossref_primary_10_1080_17434440_2025_2517173 crossref_primary_10_1089_end_2024_0640 crossref_primary_10_1007_s42250_023_00778_1 crossref_primary_10_1055_s_0042_1759701 crossref_primary_10_1016_j_ctim_2024_103067 crossref_primary_10_1016_j_eururo_2024_07_011 crossref_primary_10_1089_end_2022_0607 crossref_primary_10_3390_ijms24065486 crossref_primary_10_3389_fendo_2023_1287212 crossref_primary_10_1089_end_2022_0654 crossref_primary_10_1097_JU9_0000000000000033 crossref_primary_10_1007_s13629_024_00453_1 crossref_primary_10_1016_j_ucl_2025_07_007 crossref_primary_10_1007_s00345_023_04486_w crossref_primary_10_1016_j_euf_2024_05_009 crossref_primary_10_1016_j_urology_2023_10_038
Cites_doi	10.1016/j.eururo.2013.10.040 10.1016/j.juro.2013.05.116 10.1097/JU.0000000000001778 10.1097/JU.0000000000002183 10.1016/S0090-4295(00)00828-1 10.1097/JU.0000000000000499 10.2147/CEOR.S148195 10.1016/j.jval.2018.04.987 10.3389/fonc.2020.00103 10.1136/bmjopen-2016-012360 10.1016/j.juro.2011.09.052 10.2165/00019053-199609050-00007 10.3310/hta12350 10.1586/14737167.8.2.165 10.1016/j.juro.2015.10.181 10.1097/JU.0000000000002184
ContentType	Journal Article
Copyright	COPYRIGHT 2022 Public Library of Science 2022 Chughtai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 Chughtai et al 2022 Chughtai et al
Copyright_xml	– notice: COPYRIGHT 2022 Public Library of Science – notice: 2022 Chughtai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 Chughtai et al 2022 Chughtai et al
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA
DOI	10.1371/journal.pone.0266824
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Agricultural Science Database MEDLINE MEDLINE - Academic CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General)
DocumentTitleAlternate	Health economic analysis of treatment options in BPH
EISSN	1932-6203
ExternalDocumentID	2650397155 oai_doaj_org_article_0a37290c734741a79f88c6dbed82b69f PMC9012364 A700580223 35427376 10_1371_journal_pone_0266824
Genre	Network Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article
GeographicLocations	United States New York United States--US Germany
GeographicLocations_xml	– name: United States – name: New York – name: United States--US – name: Germany
GrantInformation_xml	– fundername: ;
GroupedDBID	--- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ ALIPV CGR CUY CVF ECM EIF IPNFZ NPM RIG BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM
ID	FETCH-LOGICAL-c6074-9927f1f51ebde91aacbbc72f69add42cb569b54a4f70e4656021fda41684f5ac3
IEDL.DBID	7RV
ISSN	1932-6203
IngestDate	Sun May 01 00:10:39 EDT 2022 Tue Oct 14 14:48:23 EDT 2025 Tue Nov 04 01:55:46 EST 2025 Fri Sep 05 12:17:04 EDT 2025 Tue Oct 07 07:47:54 EDT 2025 Sat Nov 29 13:14:24 EST 2025 Sat Nov 29 10:22:59 EST 2025 Wed Nov 26 09:42:23 EST 2025 Wed Nov 26 09:30:21 EST 2025 Thu May 22 21:24:01 EDT 2025 Wed Jul 30 01:47:31 EDT 2025 Sat Nov 29 04:06:56 EST 2025 Tue Nov 18 20:59:29 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Language	English
License	This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c6074-9927f1f51ebde91aacbbc72f69add42cb569b54a4f70e4656021fda41684f5ac3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 KN, DG and SF also contributed equally to this work. Competing Interests: B Chughtai is a paid clinical consultant for Boston Scientific, MedeonBio, Olympus, and Allergan as well as an investigator for Teleflex. S Rojanasarot, B Cutone, and S Bhattacharyya are employees of Boston Scientific. K Neeser, D Gultyaev, and S Fu are employees of Certara Evidence & Access. K McVary is a principal investigator for NIDDK and Urovant. He is a paid clinical consultant for Boston Scientific and MedeonBio. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
ORCID	0000-0003-2102-7520
OpenAccessLink	https://www.proquest.com/docview/2650397155?pq-origsite=%requestingapplication%
PMID	35427376
PQID	2650397155
PQPubID	1436336
PageCount	e0266824
ParticipantIDs	plos_journals_2650397155 doaj_primary_oai_doaj_org_article_0a37290c734741a79f88c6dbed82b69f pubmedcentral_primary_oai_pubmedcentral_nih_gov_9012364 proquest_miscellaneous_2651686637 proquest_journals_2650397155 gale_infotracmisc_A700580223 gale_infotracacademiconefile_A700580223 gale_incontextgauss_ISR_A700580223 gale_incontextgauss_IOV_A700580223 gale_healthsolutions_A700580223 pubmed_primary_35427376 crossref_primary_10_1371_journal_pone_0266824 crossref_citationtrail_10_1371_journal_pone_0266824
PublicationCentury	2000
PublicationDate	20220415
PublicationDateYYYYMMDD	2022-04-15
PublicationDate_xml	– month: 4 year: 2022 text: 20220415 day: 15
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: San Francisco – name: San Francisco, CA USA
PublicationTitle	PloS one
PublicationTitleAlternate	PLoS One
PublicationYear	2022
Publisher	Public Library of Science Public Library of Science (PLoS)
Publisher_xml	– name: Public Library of Science – name: Public Library of Science (PLoS)
References	C. Welliver (pone.0266824.ref001) 2020; 203 H.W. Chen (pone.0266824.ref019) 2012; 187 J.F. Baladi (pone.0266824.ref018) 1996; 9 S.J. Ackerman (pone.0266824.ref020) 2000; 56 K.T. McVary (pone.0266824.ref028) 2021; 206 K.T. McVary (pone.0266824.ref009) 2016; 195 L.B. Lerner (pone.0266824.ref005) 2021; 206 pone.0266824.ref025 C.G. Roehrborn (pone.0266824.ref014) 2013; 190 pone.0266824.ref024 A.Z. Burnett (pone.0266824.ref026) 2018; 21 pone.0266824.ref022 L.B. Lerner (pone.0266824.ref006) 2021; 206 C. Rognoni (pone.0266824.ref021) 2017; 7 J.D. Pinto (pone.0266824.ref002) 2016; 13 A.Y. Zhang (pone.0266824.ref003) 2018; 4 M. Haacker (pone.0266824.ref012) 2020; 35 pone.0266824.ref017 A. Harat (pone.0266824.ref027) 2020; 10 U.S. Centers for Medicare (pone.0266824.ref023) 2019 SD Grosse (pone.0266824.ref010) 2008; 8 E. Arias (pone.0266824.ref013) 2020; 69 A. Bachmann (pone.0266824.ref015) 2014; 65 J.C. Ulchaker (pone.0266824.ref007) 2018; 10 L. Feinstein (pone.0266824.ref004) 2018 B. Chugtai (pone.0266824.ref008) 2021; 8 pone.0266824.ref011 T. Lourenco (pone.0266824.ref016) 2008; 12
References_xml	– volume: 65 start-page: 931 issue: 5 year: 2014 ident: pone.0266824.ref015 article-title: 180-W XPS greenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European multicentre randomised trial—The GOLIATH study publication-title: Eur Urol. doi: 10.1016/j.eururo.2013.10.040 – start-page: 78 volume-title: Urologic diseases in America year: 2018 ident: pone.0266824.ref004 – volume: 190 start-page: 2161 issue: 6 year: 2013 ident: pone.0266824.ref014 article-title: The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. study publication-title: J Urol doi: 10.1016/j.juro.2013.05.116 – volume: 206 start-page: 715 issue: 3 year: 2021 ident: pone.0266824.ref028 article-title: Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia publication-title: J Urol doi: 10.1097/JU.0000000000001778 – ident: pone.0266824.ref011 – ident: pone.0266824.ref017 – volume: 206 start-page: 806 issue: 4 year: 2021 ident: pone.0266824.ref005 article-title: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management publication-title: J Urol doi: 10.1097/JU.0000000000002183 – volume: 56 start-page: 972 issue: 6 year: 2000 ident: pone.0266824.ref020 article-title: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: Part I-methods publication-title: Urology doi: 10.1016/S0090-4295(00)00828-1 – ident: pone.0266824.ref025 – volume: 203 start-page: 171 issue: 1 year: 2020 ident: pone.0266824.ref001 article-title: Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: The urologic diseases in America project publication-title: J Urol doi: 10.1097/JU.0000000000000499 – volume: 10 start-page: 29 year: 2018 ident: pone.0266824.ref007 article-title: Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia publication-title: Clinicoecon Outcomes Res doi: 10.2147/CEOR.S148195 – volume: 69 start-page: 1 issue: 12 year: 2020 ident: pone.0266824.ref013 article-title: United States life tables, 2018 publication-title: Natl Vital Stat Rep – volume: 21 start-page: S143 year: 2018 ident: pone.0266824.ref026 article-title: The economic burden of erectile dysfunction and related comorbidities: A medicare perspective publication-title: Value Health doi: 10.1016/j.jval.2018.04.987 – volume: 10 start-page: 103 year: 2020 ident: pone.0266824.ref027 article-title: A Cost-effectiveness and quality of life analysis of different approaches to the management and treatment of localized prostate cancer publication-title: Front Oncol doi: 10.3389/fonc.2020.00103 – volume: 7 start-page: e012360 issue: 1 year: 2017 ident: pone.0266824.ref021 article-title: Healthcare resource consumption for intermittent urinary catheterisation: Cost-effectiveness of hydrophilic catheters and budget impact analyses publication-title: BMJ Open doi: 10.1136/bmjopen-2016-012360 – year: 2019 ident: pone.0266824.ref023 publication-title: Medicaid Services. Standard analytical files – volume: 35 start-page: 107 issue: 1 year: 2020 ident: pone.0266824.ref012 article-title: On discount rates for economic evaluations in global health. publication-title: Health Policy Plan – volume: 8 start-page: 8 issue: 1 year: 2021 ident: pone.0266824.ref008 article-title: Cost-effectiveness and budget impact of emerging minimally invasive surgical treatments for benign prostatic hyperplasia. publication-title: JHEOR – volume: 187 start-page: 178 issue: 1 year: 2012 ident: pone.0266824.ref019 article-title: Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder publication-title: J Urol doi: 10.1016/j.juro.2011.09.052 – volume: 4 start-page: 2377960818811773 year: 2018 ident: pone.0266824.ref003 article-title: Prevalence, burden, and treatment of lower urinary tract symptoms in men ged 50 and older: A systematic review of the literature. publication-title: SAGE Open Nurs – volume: 9 start-page: 443 issue: 5 year: 1996 ident: pone.0266824.ref018 article-title: An economic evaluation of finasteride for treatment of benign prostatic hyperplasia publication-title: Pharmacoeconomics doi: 10.2165/00019053-199609050-00007 – volume: 13 start-page: 309 issue: 3 year: 2016 ident: pone.0266824.ref002 article-title: Health-related quality of life and psychological well-being in men with benign prostatic hyperplasia: An integrative review publication-title: JJNS – volume: 12 issue: 35 year: 2008 ident: pone.0266824.ref016 article-title: Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement publication-title: Health Technol Assess doi: 10.3310/hta12350 – volume: 8 start-page: 165 issue: 2 year: 2008 ident: pone.0266824.ref010 article-title: Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold publication-title: Expert Rev Pharmacoecon Outcomes Res doi: 10.1586/14737167.8.2.165 – volume: 195 start-page: 1529 issue: 5 year: 2016 ident: pone.0266824.ref009 article-title: Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia publication-title: J Urol doi: 10.1016/j.juro.2015.10.181 – volume: 206 start-page: 818 issue: 4 year: 2021 ident: pone.0266824.ref006 article-title: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II-surgical evaluation and treatment publication-title: J Urol doi: 10.1097/JU.0000000000002184 – ident: pone.0266824.ref024 – ident: pone.0266824.ref022
SSID	ssj0053866
Score	2.5222616
SecondaryResourceType	review_article
Snippet	Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety,...
SourceID	plos doaj pubmedcentral proquest gale pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	e0266824
SubjectTerms	Aged Analysis Biology and Life Sciences Clinical trials Cost analysis Cost-Benefit Analysis Costs Economic aspects Genital diseases Government programs Health aspects Health care policy Health services Humans Hyperplasia Hypertrophy Intubation Literature reviews Male Markov chains Medical fees Medicare Medicine and Health Sciences Meta-analysis Middle Aged Patients Physical Sciences Prostate Prostatic Hyperplasia - complications Quality of Life Social Sciences Transurethral Resection of Prostate - adverse effects Treatment Outcome United States Urinary tract Urogenital system Vaporization Water vapor
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQigMXRHk10IJBSIDUtJvEsePjgqjgUhAv9RbZjt1daZWsNrtI_Iv-ZGZsb9SgSuXANR5HuzPj8TfKzDeEvML52rKqdAqpV5li62KqwJFSKyrHuWsA8TI_bEKcnVXn5_LLlVFfWBMW6IGD4k6mCj8sTY0oGFx-SkhXVYY32jZVrrl0GH2nQu6SqRCD4RRzHhvlCpGdRLscr7rWHkPWwaucjS4iz9c_ROXJatn110HOvysnr1xFp_fI3Ygh6Sz89j1yy7b3yV48pT19E6mk3z4glzOKNeNrOw916lRFDhLaObprijyiobPyNz5cLpw9ArEGNvabNJR7xIhIu-0GXmf9bjj8dKhSp12ojaEAgam27eKipSvsJ0E-WDqHXHe98v2aD8mP0w_f339M4wyG1HAs1ZQyFy5zZWZ1Y2WmlNHaiNxxCYGR5UaXXOqSKebE1CL3GmAG1yiAeRVzpTLFIzJpQev7hDqbaa2YmDZOszITFWOmgYAhG8wamU1IsTNIbSJBOc7JWNb-q5uARCXot0Yz1tGMCUmHXatA0HGD_Du09SCL9Nr-AThdHZ2uvsnpEvIcPaUOvapDkKhnAsc0AiwqEvLSSyDFRos1PBdq2_f1p88__0Ho29eR0Oso5DpQh1GxbwL-E1J3jSQPRpIQKMxoeR_9eqeVvs4BnQMcBUQJO3e-fv3yi2EZX4p1ea3ttl4GLA2oVSTkcTgag2aLkgE2FjwhYnRoRqofr7SLuWc4l55ZkD35H7Z6Su7k2LKC_JzlAZls1lt7SG6bX5tFv37mw8YfC2J00Q priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Library of Science (PLoS) Journals Open Access dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELeg8MALY3wtMMAgJEBaRpM4dvxYEBVIaEx8aW-R7dhrpSqpmnYS_wV_MneOG8i0CXiN76zk7Lv8Tr77mZDneL-2LAodQ-qVx9i6GCvYSLEVhePcVYB4mb9sQhwdFScn8vh3onjuBD8Tyetg08NlU9tDyBh4kbKr5FqacY7J1vT44zbygu9yHtrjLtMc_H48S38fi0fLRdNeBDTP10v-8QOa7vzvq98iNwPUpJNub-ySK7a-TXaDM7f0ZWCcfnWH_JxQLC1f2VlXzk5VoCqhjaPb3skD2jVg_sCHi7mzByBWgWK7jruqkBA4abNZw3TWa0OMoH0xO226EhoKSJlqW89Pa7rEthOkjaUzSIlXS9_WeZd8m777-vZ9HK5qiA3Hik4pU-ESlydWV1YmShmtjUgdlxA_WWp0zqXOmWJOjC1StAG0cJUCNFgwlyuT3SOjGqy0R6izidaKiXHlNMsTUTBmKogrssLkktmIZNsVLE3gMcfrNBalP5wTkM909i3R7GUwe0TiXmvZ8Xj8Rf4Nbo5eFlm4_QNY3zI4dTlWeOg5NiJjAMyUkK4oDK-0rYpUc-ki8gS3Vtm1tPaxpJwIvM0R0FMWkWdeApk4aiz1OVWbti0_fPr-D0JfPg-EXgQh14A5jArtFfBNyPA1kNwfSEI8MYPhPXSErVXaMgUQD6gVgCdobp3j4uGn_TBOiuV7tW02XgZWGsCtiMj9zpd6y2Y5AwgteETEwMsGph-O1POZJ0KXnoCQPbj8jR-SGyn2qyA5Z75PRuvVxj4i183Zet6uHvvo8QsFt3Fg priority: 102 providerName: Public Library of Science
Title	A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia
URI	https://www.ncbi.nlm.nih.gov/pubmed/35427376 https://www.proquest.com/docview/2650397155 https://www.proquest.com/docview/2651686637 https://pubmed.ncbi.nlm.nih.gov/PMC9012364 https://doaj.org/article/0a37290c734741a79f88c6dbed82b69f http://dx.doi.org/10.1371/journal.pone.0266824
Volume	17
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fb9MwELeg44EXYPxbYRSDkABp6ZrUiZMn1E6rmMZKtMFUeIkSx24rVUloWiS-BR-ZO8cJBE2AxMs9xOcose_OZ_vud4S8wPrage8nFmy9XAtTF60YBMmS3Feep1LweJkuNsGnU382C0Jz4FaasMraJmpDneYCz8gPHXAlYO2E5e9N8cXCqlF4u2pKaFwnOzb6xiDP_PyytsSgy55n0uWG3D40s9Mv8kz2Ye_h-Q5rLUcatb-xzZ1ilZdXOZ6_x0_-siBNbv_vr9wht4wrSkeV7OySazK7S3aNspf0lUGkfn2PfB9RDD1fy0UV7k5jA2VCc0Xr3MoDWiVofsOHq6WSB8CWQsdyY1VRI8aw0ny7gddJ3RtsCG2C3WlehdhQ8KRpIrPlPKMFpqUgrCxdwJZ5Xei0z_vk4-T4w9Fby5RysISHEZ9B4HBlK9eWSSoDO45FkgjuKC8A-8ockbhekLgsZooPJEK4geuh0hi8RZ8pNxbDB6STwbTtEaqknSQx44NUJcy1uc-YSMHuBCluPpnskmE9o5EwOOdYbmMV6cs7DvudanwjlIPIyEGXWE2vosL5-Av_GIWl4UWUbv0gX88jo_TRIMZL0YHgQwaOW8wD5fvCSxOZ-k7iBapLnqKoRVXKa2NrohHHao_gXQ275LnmQKSODEOB5vG2LKOT95f_wHRx3mJ6aZhUDsMhYpN-Af-ECGAtzv0WJ9gb0WreQ8WoR6WMfooz9KwF_urmZ00zvhTD-zKZbzUPzDQ4v7xLHla61Yzs0GXgYnOvS3hL61pD327JlgsNlB5ogEL26M-f9ZjcdDCnBQE83X3S2ay38gm5Ib5uluW6py0K0hnX1AfqH9k9sjM-nobnPX2IA3QSvgN6Ou4DPRucIuWhphdAQ_cz9AhPzsJPPwC5yo-9
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgAQXoLxqKHRBIECq29hee-0DQuFRNWopVSmo4mLs9W4SKbJNnIDyL_gl_EZm1muDUQVceuDqnV0l45lvZrzzIOQhzteOwjC1IfTybSxdtBMQJFvyUAWBysDjZXrYBD84CE9OosMV8r2phcG0ygYTNVBnhcBv5NsuuBJgO8H8PS8_2zg1Cm9XmxEatVjsyeVXCNmqZ8NX8H4fue7O6-OXu7aZKmCLAJMPo8jlylG-I9NMRk6SiDQV3FVBBKrOXJH6QZT6LGGK9yV2EwMrqLIEHJeQKT8RHpx7jpxnzO2jFh36HxvkB-wIAlOe53Fn20jDVlnkcgtinSB0Wcf86SkBrS3oldOiOs3R_T1f8xcDuHPlf2PdVXLZuNp0UOvGKlmR-TWyasCsok9Mx-2n18m3AcXU-pkc1-n8NDGtWmihaFM7uknrAtQlPpxOlNwEsgw2VnO7zooxhoMWizkcJ_VuwEjaJvPTok4hohAp0FTmk1FOSyy7wba5dLws5azUZa03yPsz4cxN0stBTNYIVdJJ04TxfqZS5js8ZExkgKtRhsE1kxbxGgmKhenjjuNEprG-nOQQz9X8jVHuYiN3FrHbXWXdx-Qv9C9QOFta7EKuHxSzUWxALe4neOnbF9xj4JgmPFJhKIIslVnopkGkLLKBoh3XJb0tlsYDjtMswXv0LPJAU2AnkhxTnUbJoqri4dsP_0D07qhD9NgQqQLYIRJTXgL_CTucdSjXO5SAp6KzvIaK2HClin-qD-xsFOz05fvtMh6K6Yu5LBaaBt40OPfcIrdqXW456_kMQggeWIR3tLzD-u5KPhnrRvCRbsDIbv_5Z22Qi7vHb_bj_eHB3h1yycX6HWxW6q-T3ny2kHfJBfFlPqlm9zSaUfLprDHgB3JY4UQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lj9MwELaWghAXYHltYWENAgHSZtskTpwcECosFdWiUvHSiktwHLutVCWhaUH9F_wefh0ziRMIWgGXPXCNx1YzmWc98w0h93G-dhgEsQWpl2dh66IlQJAsxQPt-zqBiJeVwyb4eBwcH4eTLfK97oXBssraJpaGOskk_kfecyCUAN8J7q-nTVnE5HD4NP9s4QQpvGmtx2lUInKkNl8hfSuejA7hWz9wnOGLd89fWmbCgCV9LEQMQ4drW3u2ihMV2kLIOJbc0X4Ias8cGXt-GHtMMM37CpHFwCPqREAQEzDtCenCuWfIWY4vCro08T7WXgDsiO-bVj2X2z0jGQd5lqoDyHv8wGEtV1hODGj8QidfZMVJQe_vtZu_OMPhpf-ZjZfJRROC00GlM9tkS6VXyLYxcgV9ZJC4H18l3wYUS-6XalaV-VNhIFxopmndU7pPq8bUDT5czLXaB7IENhYrq6qWMQ6FZusVHKfK3WA7aVPkT7OqtIhCBkFjlc6nKc2xHQfhdOlsk6tlXra7XiPvT4Uz10knBZHZIVQrO44F4_1Ex8yzecCYTMDehgkm3Ux1iVtLUyQNvjuOGVlE5aUlhzyv4m-EMhgZGewSq9mVV_gmf6F_hoLa0CI6efkgW04jY-yivsDL4L7kLoOAVfBQB4H0k1glgRP7oe6SPRTzqGr1bWxsNOA45RKiSrdL7pUUiFCSopBOxboootHrD_9A9PZNi-ihIdIZsEMK03YC74TIZy3K3RYl2FnZWt5Bpay5UkQ_VQl21sp28vLdZhkPxbLGVGXrkga-NAT9vEtuVHrdcNb1GKQW3O8S3tL4FuvbK-l8VgLEhyUwI7v555-1R86D6kevRuOjW-SCg209iGHq7ZLOarlWt8k5-WU1L5Z3SsNGyafTNgE_ALGa6g4
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comprehensive+analysis+of+clinical%2C+quality+of+life%2C+and+cost-effectiveness+outcomes+of+key+treatment+options+for+benign+prostatic+hyperplasia&rft.jtitle=PloS+one&rft.au=Chughtai%2C+Bilal&rft.au=Rojanasarot%2C+Sirikan&rft.au=Neeser%2C+Kurt&rft.au=Gultyaev%2C+Dmitry&rft.date=2022-04-15&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=17&rft.issue=4&rft.spage=e0266824&rft_id=info:doi/10.1371%2Fjournal.pone.0266824&rft.externalDBID=IOV&rft.externalDocID=A700580223
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon